US › Healthcare

Soligenix Inc. (SNGX)

US · Healthcare · Biotechnology

$0.38-0.13%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-2.8M
Profit YoY
+12.7%
EPS
$-0.28
EPS estimate
$-0.30

EPS came in at -0.28 against a street estimate of -0.30 — a beat of 6.7%.

Key statistics

Market cap
$5.5M
Forward P/E
12.3
P/B
1.78
Book value
$0.29
EPS (TTM)
$-1.45
52-week high
$6.23
52-week low
$0.28
50-day MA
$0.44
200-day MA
$1.03
Beta
1.92

Analyst view

Analysts rate Soligenix Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $1.75.

Shareholding

Insiders
6.74%
Institutions
5.33%

Largest institutional holders

FundStake
Geode Capital Management, LLC0.81%
Vanguard Capital Management, LLC0.39%
Vanguard Fiduciary Trust Co0.36%
XTX Topco Ltd0.14%
Morgan Stanley - Brokerage Accounts0.02%
UBS Group AG0.02%
SBI Securities Co Ltd0.00%
JPMorgan Chase & Co0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Soligenix Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.